Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESETTLE
NCT05574439Phase 4Completed
- Start
- May 2022
- Primary completion
- Apr 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of semaglutide in obesity (5 arms). Primary endpoint: Change in Body Mass Index at 68 weeks. Started May 2022; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05574439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05574439.